Welcome to our dedicated page for Mustang Bio SEC filings (Ticker: MBIO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to Mustang Bio, Inc. (Nasdaq: MBIO) SEC filings, offering a regulatory view of a clinical-stage biopharmaceutical company focused on cell therapies for difficult-to-treat cancers. Mustang Bio states that its common stock is registered under the Securities Exchange Act of 1934 and that it files periodic reports with the U.S. Securities and Exchange Commission (SEC).
Through this filings page, users can review annual reports on Form 10-K and quarterly reports on Form 10-Q, which typically describe Mustang Bio’s clinical-stage status, key product candidates such as MB-101, MB-108, and the MB-109 combination regimen, and the risks and uncertainties associated with its development programs. These reports also generally discuss the company’s strategy of licensing or acquiring rights to cell therapy technologies, funding research and development, and potentially outlicensing or commercializing those technologies.
Investors and researchers can also look for registration statements and related filings that correspond to Mustang Bio’s public offerings of common stock and warrants, as referenced in its press releases. These documents can provide additional detail on how the company raises capital to support its clinical programs and operational needs.
Stock Titan enhances this information with AI-powered summaries that help explain the content of complex filings, highlight key risk factors, and point out disclosures related to clinical trials, funding needs, and listing requirements. Real-time updates from EDGAR, combined with AI-generated highlights, make it easier to follow Mustang Bio’s regulatory history and understand how its SEC disclosures relate to its cell therapy pipeline and Nasdaq listing.
Mustang Bio (MBIO) reported Q3 2025 results with a net loss of $0.468 million, improved from a $1.410 million loss a year ago, as lower operating costs and one-time credits reduced expenses. Cash and cash equivalents were $18.984 million at September 30, 2025, up from $6.839 million at year-end, and total stockholders’ equity was $9.771 million.
The company completed a 1-for-50 reverse split in January and raised capital through a February 2025 equity offering with net proceeds of approximately $6.8 million, followed by July warrant exercises adding about $7.1 million; an at-the-market program contributed $0.6 million year-to-date. Management disclosed “substantial doubt” about the ability to continue as a going concern without additional financing.
Pipeline updates include FDA Orphan Drug Designations for MB-108 and MB-101 and exploration of an investigator-sponsored MB-109 study at City of Hope as early as the second quarter of 2026. In September 2025, Fred Hutch provided notice of intent to terminate the CD20 license, subject to a 90‑day cure period, and the parties plan to negotiate terms.
Fortress Biotech amended its Schedule 13D for Mustang Bio (MBIO) to report it now beneficially owns 258,858 shares of Mustang Bio common stock, representing 4.0% of the outstanding common stock. The holding includes 250,000 shares of Mustang Bio Class A preferred stock (convertible into 333 common shares) and 1,333 common shares underlying long‑dated warrants reserved for Fortress officers. Fortress received 59,334 shares as Offering Equity Grants under a Founders Agreement that grants a 2.5% equity fee on financings. The filing notes Fortress ceased to beneficially own more than 5% of Mustang Bio on September 29, 2025.
Mustang Bio, Inc. amended its at-the-market common stock offering to allow sales of up to $4,750,000 in aggregate through H.C. Wainwright & Co. under its existing shelf registration. The company is updating the capacity it may use under General Instruction I.B.6 of Form S-3 based on its current public float. As of September 5, 2025, the public float was $20,677,132, calculated from 6,190,758 shares held by non-affiliates at a reference price of $3.34 per share. Over the prior 12-month period, Mustang Bio has offered and sold $2,102,821 of securities under this I.B.6 limitation, and future ATM sales remain subject to the one-third public float cap and the amount registered on the Form S-3.
The Reporting Persons—Intracoastal Capital LLC together with Mitchell P. Kopin and Daniel B. Asher—report beneficial ownership of 185,527 Mustang Bio common shares, representing 4.99% of the company’s common stock. That amount reflects shares issuable upon exercise of a warrant held by Intracoastal and is reported as shared voting and dispositive power with no sole voting or dispositive power.
The filing discloses that two warrants contain blocker provisions preventing exercise to the extent ownership would exceed 4.99%, and states that without those blockers the Reporting Persons may be deemed to beneficially own 1,328,904 shares. The Reporting Persons certify the securities were not acquired to change or influence control of the issuer.
Mustang Bio, Inc. is a clinical-stage biopharmaceutical company focused on CAR T and oncolytic virus therapies. For the quarter ended June 30, 2025, the company reported cash and cash equivalents of $12.7 million and total assets of $13.0 million, funded largely by equity financings. Total liabilities were $10.2 million and stockholders' equity improved to $2.9 million from a deficit of $3.9 million at year-end 2024.
Operating results show a substantially reduced loss compared with prior-year periods: net loss was $762,000 for the quarter and $915,000 for the six months ended June 30, 2025, versus significantly larger losses in 2024. The company generated approximately $6.8 million net proceeds from a February 2025 equity offering and ~$0.6 million from ATM sales during the period; subsequent July 2025 warrant exercises raised ~$7.1 million.
Management discloses substantial doubt about the company's ability to continue as a going concern and states additional financing will be required to advance clinical programs.
FAQ
What is the current stock price of Mustang Bio (MBIO)?
What is the market cap of Mustang Bio (MBIO)?
